NSRX
NSRX clinical trials: Nasus Pharma Ltd
Every trial on ClinicalTrials.gov where Nasus Pharma Ltd is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 7
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
NSRX on the catalyst calendar · NSRX registry changes
- Primary completion Jan 2027Sponsor estimatePhase 1NCT07868861A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy AdultsNasus Pharma · Chemotherapy-Induced Nausea and Vomiting (CINV)RecruitingNSRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2026Sponsor estimatePhase 1/Phase 2NCT07228325Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic RhinitisNasus Pharma · AnaphylaxisEnrolling by invitationNSRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 12, 2026Sponsor estimatePhase 2/Phase 3NCT07045701FMXIN002 in Patients at Risk of AnaphylaxisNasus Pharma · Anaphylaxis FoodEnrolling by invitationNSRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2, 2024ActualPhase 1/Phase 2NCT06205134Comparative Bioavailability of Intranasal EpinephrineNasus Pharma · AnaphylaxisCompletedNSRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 28, 2021ActualPhase 1NCT04696822Bioavailability of Nasal EpinephrineNasus Pharma · AnaphylaxisCompletedNSRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 30, 2021ActualPhase 1NCT04713709A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres PowderNasus Pharma · Opioid OverdoseCompletedNSRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2, 2021ActualNo phase registeredNCT05252468COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).Nasus Pharma · COVID-19CompletedNSRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner